Semaglutide News and Research

Latest Semaglutide News and Research

AclarusDx Alzheimer’s test now available as RUO product

ExonHit Therapeutics is pleased to announce that AclarusDx™ Alzheimer’s test (formerly known as EHT Dx21), its blood-based test for the detection of Alzheimer’s disease (AD), is now available as a Research Use Only (RUO) product for pharmaceutical companies and leading academic centers conducting clinical trials in Alzheimer’s disease.

3 Dec 2009

Roche announces results of phase III taspoglutide study in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s research and developed by Roche.

2 Dec 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Third-quarter 2009 financial results announced by Inhibitex

Inhibitex, Inc., today announced its financial results for the third quarter ended September 30, 2009. The Company held cash, cash equivalents and short-term investments of $21.1 million at September 30, 2009, as compared to $33.1 million at December 31, 2008.

6 Nov 2009

Eating a meal quickly curtails the release of hormones in the gut and can lead to overeating

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), eating a meal quickly, as compared to slowly, curtails the release of hormones in the gut that induce feelings of being full. The decreased release of these hormones, can often lead to overeating.

4 Nov 2009

Eat slowly to avoid overeating

4 Nov 2009

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ExonHit Therapeutics yesterday presented clinical data on the validation set “Alzheimer patients versus healthy controls” for AclarusDx™ (formerly EHT Dx21), its blood-based diagnostic test for the detection of Alzheimer’s disease (AD), at the 2nd Conference of Clinical Trials on Alzheimer’s Disease (CTAD) in Las Vegas, USA.

30 Oct 2009

Roche discloses the results of first Phase III clinical study using Taspoglutide

Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s Research.

29 Oct 2009

Lovelace Respiratory Research Institute and Brigham and Women's Hospital collaborate on respiratory diseases research

Lovelace Respiratory Research Institute (LRRI) recently announced the formation of a research agreement between the Division of Pulmonary and Critical Care Medicine of the Department of Medicine at Brigham and Women's Hospital (BWH), teaching hospital of Harvard Medical School in Boston.

28 Oct 2009

DNA Precision offers services for genetic research and healthcare research

DNA Precision has begun offering services for genetic research and healthcare research. These include gene discovery, Agilent ® microarray processing and bioinformatics. DNA Precision is a division of EcoArray, Inc., a 7-year old environmental genomics firm in Gainesville, FL.

15 Oct 2009

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

PDS Biotechnology Corporation today announced that the company has completed GLP toxicology studies of its lead HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the evaluation of toxicity, all demonstrated a very safe profile of the drug and PDS Biotech's platform Versamune((TM)) technology.

6 Oct 2009

Januvia in combination with metformin or taken alone lowers blood sugar

A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two years.

29 Sep 2009

Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that DispersinB® Topical Wound Gel has passed the FDA-recommended Cytotoxicity and Primary Skin Irritation tests conducted by WuXi AppTec Inc. (St. Paul, MN) in compliance with Good Laboratory Practice (GLP). Thus, DispersinB® wound gel is considered non-cytotoxic and non-irritant.

28 Sep 2009

New Fragment Screening Platform from Selcia

Selcia Ltd, a worldwide industry leading C-14 custom radiolabelling provider and drug discovery company this week launched their new Fragment Screening Platform and unveiled their new brand as part of ambitious international expansion plans.

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

BCLI collaborates with HBI to complete pre-clinical safety experiments

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into a strategic agreement with Harlan Biotech Israel Ltd (HBI), a leading Good Laboratory Practice contractor, in order to complete pre-clinical safety experiments for the company’s innovative therapy for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease).

15 Sep 2009

Clinical Logistics partners with a GLP compliant laboratory

Clinical Logistics is pleased to announce the introduction of specimen storage services through a partnership with Gentris Corporation (Gentris), a GLP compliant laboratory, located in Morrisville, North Carolina.

13 Sep 2009

Oral GLP-1 Analog approved for human clinical trial

Oramed Pharmaceticals, Inc., a developer of oral drug delivery systems, announced today that it has received approval from the Institutional Review Board (IRB) to commence human clinical trials of an oral GLP-1 Analog.

10 Sep 2009

Nanoemulsion-based adjuvant increases immunity and cross protection against influenza

NanoBio Corp. announced today that data from a large ferret study indicates that its intranasal, nanoemulsion-based adjuvant elicits robust immunity and cross protection against influenza using 1/15th of the standard antigen dose, without evidence of toxicity or tolerability concerns.

9 Sep 2009

Grant awarded to two researchers to study the role of GLP-1 in people at risk for or with diabetes

The American Diabetes Association Research Foundation has selected two scientists, University of Virginia Health System researcher Zhenqi Liu, MD, and Stanford University School of Medicine researcher Gerald Reaven, MD, to receive the American Diabetes Association-Novo Nordisk Clinical/Translational Research Award. This $1.2 million grant program supports efforts to study the effects of intestinal hormones, such as glucagon-like peptide-1 (GLP-1), on obesity and pre-diabetes, two risk factors for type 2 diabetes and cardiovascular disease.

2 Sep 2009

Semaglutide News and Research

Latest Semaglutide News and Research

AclarusDx Alzheimer’s test now available as RUO product

Roche announces results of phase III taspoglutide study in diabetes patients

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Third-quarter 2009 financial results announced by Inhibitex

Eating a meal quickly curtails the release of hormones in the gut and can lead to overeating

Eat slowly to avoid overeating

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

Roche discloses the results of first Phase III clinical study using Taspoglutide

Lovelace Respiratory Research Institute and Brigham and Women's Hospital collaborate on respiratory diseases research

DNA Precision offers services for genetic research and healthcare research

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

Januvia in combination with metformin or taken alone lowers blood sugar

Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests

New Fragment Screening Platform from Selcia

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

BCLI collaborates with HBI to complete pre-clinical safety experiments

Clinical Logistics partners with a GLP compliant laboratory

Oral GLP-1 Analog approved for human clinical trial

Nanoemulsion-based adjuvant increases immunity and cross protection against influenza

Grant awarded to two researchers to study the role of GLP-1 in people at risk for or with diabetes

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Semaglutide News and Research

Latest Semaglutide News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in